On the other hand, the fact that tDD EC/D improved outcomes of primary resected HER2-positive breast cancer treated with adjuvant trastuzumab, underscores the importance of incorporating dose-dense regimens into the management of patients with no contraindication to anthracyclines. Here, ERBB2 is linked to breast cancer.